%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture non répertoriées par l'AERES
%A Boullé, C.
%A Guichet, E.
%A Kouanfack, C.
%A Aghokeng Fobang, Avelin
%A Onambany, B.
%A Ikaka, C.M.
%A Ngock, E.
%A Tsoumsta, L.
%A Msellati, Philippe
%A Mpoudi-Ngolé, E.
%A Peeters, Martine
%A Delaporte, E.
%A Laurent, Christian
%T Virologic failure and human immunodeficiency virus drug resistance in rural Cameroon with regard to the UNAIDS 90-90-90 treatment targets
%D 2016
%L fdi:010085504
%G ENG
%J Open Forum Infectious Diseases
%@ 2328-8957
%K CAMEROUN
%N 4
%P ofw233 [7 ]
%R 10.1093/ofid/ofw233
%U https://www.documentation.ird.fr/hor/fdi:010085504
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2022-07/010085504.pdf
%V 3
%W Horizon (IRD)
%X Background. In rural Africa, data on virologic effectiveness of antiretroviral treatment (ART) are not sufficient to assess the gap with the UNAIDS 90-90-90 treatment targets. We investigated the prevalences of unsuppressed viral load and antiretroviral drug resistance and the profile of genotypic resistance mutations among patients routinely treated in rural Cameroon. Methods. A cross-sectional study was performed in 2013-2014 among patients sup or eq. 15 years and on first-line ART for sup. or eq. 6 months in a district hospital. Patients were offered free access to human immunodeficiency virus viral load testing. Genotypic drug resistance testing was done when the viral load was >1000 copies/mL. Multivariate logistic regression models were used to assess the relation-ship of unsuppressed viral load or antiretroviral drug resistance with sociodemographic and medical characteristics. Results. Of 407 patients (women 74.9%, median age 41.8 years, median time on ART 29.2 months), 96 (23.6%; 95% confidence interval [CI], 19.5-28.0) had unsuppressed viral load and 74 (18.2%; 95% CI, 14.6-22.3) had antiretroviral drug resistance. The prevalences of unsuppressed viral load and resistance increased with time on ART, from 12.0% and 8.0% in the 6- to 12-month group to 31.3% and 27.1% in the >72-month group, respectively. All 74 patients with antiretroviral drug resistance were resistant to nonnucleoside reverse-transcriptase inhibitors, and 57 of them were also resistant to nucleoside reverse-transcriptase inhibitors. Conclusions. Our estimations were among the highest observed in the west and central African region. The proportion of patients with virologic failure should be divided at least by 2 to reach the UNAIDS 90-90-90 treatment targets.
%$ 052MALTRA03 ; 050MEDECI